Genetic marker study in severe psoriasis with psoriatic arthritis
Treatments studied
Part of Skin clinical trials.
This study looks at a genetic marker (IL-12B) in people with severe psoriasis and psoriatic arthritis who are already on Humira. It may help understand why some people respond better to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had severe psoriasis and psoriatic arthritis for at least 6 months.
- You are not currently taking any other psoriasis treatment besides Humira, and haven't in the last 6 months.
- You do not have other autoimmune diseases (like lupus or rheumatoid arthritis), active infections, or kidney/vascular disease.
- You are not pregnant or breastfeeding.
- You have no known genetic disorders that affect your immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how inflammatory “cytokines” are expressed in people with psoriasis—both those with joint involvement and those without. It may help researchers understand what drives joint disease and guide better future monitoring or treatments.
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
This study looks at how inflammation-related genes behave in people with psoriasis. It may help researchers understand why psoriasis flares and how it could be better treated.
This study looks at immune system differences in people with moderate-to-severe psoriasis. It aims to help guide more precise (targeted) treatment choices and may improve how well treatment works for you.
This study looks at what’s happening inside the body in people with plaque psoriasis who start certain biologic medicines that target the IL-23/IL-17 immune pathway. It may help explain why these treatments work and what body changes are linked to response.
This research study measures a specific blood protein (IL-41) in people with two types of inflammatory arthritis: ankylosing spondylitis (which affects the spine) and psoriatic arthritis (which affects joints and skin). Understanding this marker may help doctors better diagnose and monitor these conditions.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.